Business
Currency:USD
2023/FY
Stock NameRevenueRatio
BRUKINSA®1.29B52.48%
Tislelizumab536.62M21.82%
Collaboration revenue268.93M10.94%
XGEVA®92.83M3.78%
REVLIMID®76.02M3.09%
POBEVCY®56.55M2.30%
BLINCYTO®54.34M2.21%
KYPROLIS®39.8M1.62%
Other22.67M0.92%
Other20.63M0.84%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.1.13B45.89%
China1.1B44.82%
Rest of World202.01M8.22%
Europe26.6M1.08%